SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Ahlman Håkan 1947) ;pers:(Nilsson Ola 1957)"

Sökning: WFRF:(Ahlman Håkan 1947) > Nilsson Ola 1957

  • Resultat 1-10 av 118
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Hashemi, S H, et al. (författare)
  • 111In-labelled octreotide binding by the somatostatin receptor subtype 2 in neuroendocrine tumours.
  • 2003
  • Ingår i: The British journal of surgery. - : Oxford University Press (OUP). - 0007-1323 .- 1365-2168. ; 90:5, s. 549-54
  • Tidskriftsartikel (refereegranskat)abstract
    • The aim of this study was to investigate the importance of somatostatin receptor subtype 2 (SSTR2) expression for 111In-labelled diethylenetriamine-pentaacetic acid (DTPA)-D-Phe1-octreotide binding and uptake of 111In in neuroendocrine tumours.
  •  
2.
  • Nilsson, Ola, 1957, et al. (författare)
  • Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours.
  • 1998
  • Ingår i: British journal of cancer. - 0007-0920. ; 77:4, s. 632-7
  • Tidskriftsartikel (refereegranskat)abstract
    • We have compared the expression of somatostatin receptor (sstr) subtypes with the outcome of somatostatin receptor scintigraphy and the effect of somatostatin receptor activation in patients with disseminated carcinoid tumours. Tumour tissues from nine patients with midgut carcinoids (ileal) and three patients with foregut carcinoids (gastric, thymic) were analysed using Northern blotting. Expression of somatostatin receptors was demonstrated in all tumours (12 out of 12), with all five receptor subtypes present in 9 out of 12 tumours. Somatostatin receptor scintigraphy using [111In]DTPA-D-Phe1-octreotide visualized tumours in all patients (12 out of 12). The 111In activity concentrations in tumour tissue (T) and blood (B) were determined in three tumours 1-7 days after injection of the radionuclide. The T/B 111In activity concentration ratios ranged between 32 and 651. Clinically, treatment with the long-acting somatostatin analogue octreotide resulted in marked symptom relief accompanied by a significant reduction in tumour markers, for example urinary-5-HIAA levels (28-71% reduction). Incubation of midgut carcinoid tumours in primary culture with octreotide (10 microM) resulted in a reduction in spontaneously secreted serotonin (45-71% reduction) and 5-HIAA (41-94% reduction). The results demonstrate that carcinoid tumours possess multiple somatostatin receptor subtypes and that somatostatin analogues such as octreotide, which preferentially bind to somatostatin receptor subtype 2 and 5, can be used in the diagnosis and medical treatment of these tumours. In the future, novel somatostatin analogues with subtype specific receptor profiles may prove to be of value for individualizing the treatment of disseminated carcinoid tumour disease.
  •  
3.
  •  
4.
  • Ahlman, Håkan, 1947, et al. (författare)
  • Aspects on diagnosis and treatment of the foregut carcinoid syndrome.
  • 1992
  • Ingår i: Scandinavian journal of gastroenterology. - 0036-5521. ; 27:6, s. 459-71
  • Tidskriftsartikel (refereegranskat)abstract
    • Eight patients with the foregut carcinoid syndrome (two gastric and six bronchial primary tumors) are reported. The patients presented with complex clinical symptoms including ectopic production of adrenocorticotrophic hormone and growth hormone-releasing factors. The most alarming symptoms were facial flush and edema, accompanied by severe bronchoconstriction, which easily was misinterpreted as asthmatic attacks. Conventional bronchodilatory drugs may be potentially dangerous in these patients, in whom combined blockade of histamine receptors and treatment with cortisone and octreotide are recommended. Owing to the patients' age and general condition individualized long-term therapy was instituted. Surgical therapy under optimal protection by drugs can be of substantial value also in patients with advanced disease. One patient with life-threatening hormonal symptoms underwent hyperthermic perfusion of the liver with cytotoxic drugs, resulting in good palliation.
  •  
5.
  • Ahlman, Håkan, 1947, et al. (författare)
  • Clinical and experimental studies on histamine producting tumors.
  • 1993
  • Ingår i: Histamine in normal and cancer cell proliferation.eds:Garcia-Caballero M, Brandes LJ, Hosoda S.. - Oxford, UK : Pergamon Press.. - 0080422020 ; , s. 197-219
  • Bokkapitel (övrigt vetenskapligt/konstnärligt)
  •  
6.
  • Ahlman, Håkan, 1947, et al. (författare)
  • Clinical efficacy of octreotide scintigraphy in patients with midgut carcinoid tumours and evaluation of intraoperative scintillation detection.
  • 1994
  • Ingår i: The British journal of surgery. - 0007-1323. ; 81:8, s. 1144-9
  • Tidskriftsartikel (refereegranskat)abstract
    • 111In-diethylenetriamine penta-acetate-D-Phe1-octreotide scintigraphy was evaluated in a group of 27 patients with disseminated midgut carcinoid tumour. Additional information gained by the intraoperative use of a scintillation detector was studied in five patients with midgut carcinoid tumours and in two with endocrine pancreatic tumours. In 19 patients tumours not recognized by non-invasive radiological methods were visualized in 27 locations, most commonly in liver and para-aortic lymph nodes. Three false-negative tumour locations were noted (ovarian and peritoneal). With guidance from scintigraphic findings, nine patients underwent surgical tumour reduction, leading to complete remission in three. Clinically suspect tumour lesions were measured by the detector in situ, and ex vivo after excision. After excision the tissue:blood activity concentration ratios were calculated. In situ measurements were helpful in the localization of tumours and in the control of adequate clearance of tumour tissue. High tissue:blood activity concentration ratios at 1, 2 and 5 days in the five patients with midgut carcinoid tumour indicate a potential role for radiation therapy with radiolabelled octreotide in patients with somatostatin receptor-positive tumours.
  •  
7.
  • Ahlman, Håkan, 1947, et al. (författare)
  • Clinical management of gastric carcinoid tumors.
  • 1994
  • Ingår i: Digestion. - 0012-2823. ; 55 Suppl 3, s. 77-85
  • Tidskriftsartikel (refereegranskat)abstract
    • Four types of gastric carcinoids have been identified: (1) multiple small body-fundus carcinoids associated with chronic atrophic gastritis type A (A-CAG); (2) sporadic solitary lesions without specific pathogenetic background (non-A-CAG); (3) carcinoidosis associated with Zollinger-Ellison/MEN 1 syndrome, and (4) rare tumors, e.g. gastrin cell tumors, neuroendocrine carcinomas and mixed endocrine-exocrine tumors. In a retrospective study of 15 patients with gastric carcinoids (11 A-CAG, 3 non-A-CAG and 1 gastrin cell tumor) over a 10-year period, the histopathological and clinical features were assessed. The A-CAG-type carcinoids were clinically silent with lymph node metastases in 2/11 cases but no hepatic metastases. The non-A-CAG-type carcinoids were malignant with disseminated disease, hormonal symptoms and increased urinary excretion of the main histamine metabolite, MeImAA. Five patients with A-CAG tumors were subjected to antrectomy to remove hypergastrinemia, which is thought to be of pathogenetic importance for these tumors. During the observation period (1.5-8 years) 1 patient developed recurrent tumors, while the other 4 showed persistent argyrophil cell hyperplasia. A prospective treatment protocol of these tumors is suggested with endoscopic removal of less numerous, small lesions as first-step therapy, followed by antrectomy at recurrence. Larger lesions should be excised in combination with antrectomy. Gastrectomy is reserved for the rare cases of invasive tumors with lymph node metastases. As evident from the outcome of patients with non-A-CAG tumors radical surgery should be performed whenever practicable.
  •  
8.
  • Ahlman, Håkan, 1947, et al. (författare)
  • Cytotoxic treatment of adrenocortical carcinoma.
  • 2001
  • Ingår i: World journal of surgery. - : Springer Science and Business Media LLC. - 0364-2313 .- 1432-2323. ; 25:7, s. 927-33
  • Tidskriftsartikel (refereegranskat)abstract
    • Adrenocortical carcinoma (ACC) is a rare, aggressive tumor that is often detected in an advanced stage. Medical treatment with the adrenotoxic drug mitotane has been used for decades, but critical prospective trials on its role in residual disease or as an adjuvant agent after surgical resection are still lacking. The concept of a critical threshold plasma level of the drug must be confirmed in controlled studies. Because individual responsiveness cannot be predicted, the use mitotane is still advised for nonresectable disease. In case of cortisol or other steroid overproduction, several drugs (e.g., ketoconazole or aminoglutethimide) may be used. Chemotherapy with single agents (e.g., doxorubicin or cisplatin) have been disappointing, with low response rates (< 30%) and a short response duration. Part of this refractoriness may be explained by the fact that ACC tumors express the multidrug-resistance gene MDR-1. Chemotherapy with multiple agents has been tested in smaller series and has resulted in significant side effects. The best results were achieved by the combination of etoposide, doxorubicin, and cisplatin associated with mitotane, achieving a response rate of 54%, including individual complete responses. To be able to make progress in treating advanced ACC disease, adjuvant multicenter trials must be encouraged. When mitotane-based therapies are used, monitored drug levels are mandatory.
  •  
9.
  • Ahlman, Håkan, 1947, et al. (författare)
  • En "ny" tumörmarkör.
  • 1996
  • Ingår i: Klinisk Kemi i Norden, 8.. - Göteborg. ; , s. 45-52
  • Bokkapitel (övrigt vetenskapligt/konstnärligt)
  •  
10.
  • Ahlman, Håkan, 1947, et al. (författare)
  • Growth regulation in carcinoid tumors.
  • 1993
  • Ingår i: Endocrinology and metabolism clinics of North America. - 0889-8529. ; 22:4, s. 889-915
  • Forskningsöversikt (refereegranskat)abstract
    • In hormone-producing tumors such as the carcinoids, overproduction of certain hormones may activate proto-oncogenes. Hormones, or growth factors, thus can be of importance for growth regulation. Information is presented on some growth factors and their receptors in this respect and on the involvement of gastrin and its receptor on tumor development in the experimental Mastomys model. The relevance of differential expression of cell adhesion molecules in endocrine tumors is discussed also.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 118
Typ av publikation
tidskriftsartikel (102)
bokkapitel (7)
konferensbidrag (5)
forskningsöversikt (4)
Typ av innehåll
refereegranskat (104)
övrigt vetenskapligt/konstnärligt (14)
Författare/redaktör
Ahlman, Håkan, 1947 (118)
Wängberg, Bo, 1953 (81)
Forssell-Aronsson, E ... (46)
Kölby, Lars, 1963 (37)
Tisell, Lars-Eric, 1 ... (23)
visa fler...
Jansson, Svante, 194 ... (22)
Fjälling, M (14)
Nilsson, Bengt E, 19 ... (12)
Khorram-Manesh, Amir ... (9)
Olausson, Michael, 1 ... (7)
Modlin, I M (7)
Tylén, Ulf, 1938 (7)
Theodorsson, E (7)
Friman, Styrbjörn, 1 ... (6)
Andersson, P (5)
Arvidsson, Yvonne, 1 ... (5)
Grimelius, L (4)
Granérus, G (4)
Cahlin, Christian, 1 ... (4)
Kristiansson, Erik, ... (3)
Mölne, Johan, 1958 (3)
Lindstedt, G (3)
Scherstén, Tore, 193 ... (3)
Lindstedt, Sven (3)
Westberg, G (3)
Stridsberg, Mats (3)
Muth, Andreas, 1974 (3)
Mcrae, A (2)
Johansson, L (2)
Svensson, J (2)
Herlenius, Gustaf, 1 ... (2)
Eriksson, B (2)
Nilsson, M (2)
Oden, A (2)
Helou, Khalil, 1966 (2)
Andersson, Mattias K ... (2)
Stenman, Göran, 1953 (2)
Hellstrand, Kristoff ... (2)
Bergström, Anders (2)
Hansson, G (2)
Bengtsson, Bengt-Åke ... (2)
Jakobsson, C E (2)
Dahlström, Annica, 1 ... (2)
Stenqvist, Ola, 1944 (2)
Lundell, Lars, 1946 (2)
Olbe, Lars (2)
McNicol, Anne M (2)
Caplin, Martyn (2)
Langen, Britta (2)
visa färre...
Lärosäte
Göteborgs universitet (118)
Uppsala universitet (7)
Chalmers tekniska högskola (5)
Språk
Engelska (112)
Svenska (6)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (89)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy